Singing and COPD: a pilot randomised controlled trial

Singing and COPD: a pilot randomised controlled trial to assess the effects of a structured 10-week programme of singing on the health-related quality of life of patients with COPD, compared with usual treatment, six-months post-baseline assessment

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

ISRCTN

Registry ID

ISRCTN42943709

Enrollment

100

Registered

2019-05-08

Start date

2019-03-18

Completion date

Unknown

Last updated

2022-08-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic obstructive pulmonary disease (COPD) Respiratory Chronic obstructive pulmonary disease

Interventions

Randomisation will be conducted by a secure remote randomisation service independent of the research team. Randomisation will employ random permuted blocks of variable length with stratification by se

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: The trial will be open to patients: 1. With a diagnosis of COPD who have received pulmonary rehabilitation (or in receipt during the recruitment period) 2. Willing to undergo the collection of assessments planned 3. Willing to be randomised to either the intervention or control group 4. Able to attend one of the two groups planned (given the proposed day and time)

Exclusion criteria

Exclusion criteria: 1. Are unable to give informed consent 2. Have comorbid conditions that make participation difficult 3. Are unable to travel independently to the venues 4. Are not sufficiently fluent in English to complete the questionnaires employed

Design outcomes

Primary

Measure	Time frame
Quality of life assessed with the COPD Assessment Test (CAT) at baseline, three months following the ten-week intervention, and then after a further three months.	—

Secondary

Measure	Time frame
Measured at baseline, three months following the ten-week intervention, and then after a further three months: 1. Breathlessness assessed using mMRC self-completion questionnaire 2. Physical health related quality of life and mental health related quality of life assessed using SF-36 v2 self-completion questionnaire 3. Generalised anxiety disorder assessed by GAD-7 (self-completion questionnaire) 4. Depression assessed by PHQ-9 (self-completion questionnaire) 5. Lung function and patterns of breathing assessed by standardised spirometry and structured light plethysmography 6. Functional exercise measured by the standardised six-minute walk test	—

Measure

Time frame

Measured at baseline, three months following the ten-week intervention, and then after a further three months: 1. Breathlessness assessed using mMRC self-completion questionnaire 2. Physical health related quality of life and mental health related quality of life assessed using SF-36 v2 self-completion questionnaire 3. Generalised anxiety disorder assessed by GAD-7 (self-completion questionnaire) 4. Depression assessed by PHQ-9 (self-completion questionnaire) 5. Lung function and patterns of breathing assessed by standardised spirometry and structured light plethysmography 6. Functional exercise measured by the standardised six-minute walk test

—

Countries

England, United Kingdom

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 4, 2026